Evidence map›Paper›PMID 42214386›Full record

ArticlemBio2026

Autologous fecal microbiota transplantation restores the infant gut microbiome and metabolome after antibiotics: a case report.

Haipeng Sun, Anna Dulencin, Thomas J Kirn, Jasmine Vo, Ivan Liachko, Deeptha Rao, Joseph Manzano-Santana, Ekta Patel, Connie Looi, Daniel B Horton and 13 more

Registry-linked trialAbstract readCase Reports
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06609980 (Fecal Microbiota Transplantation), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06609980 phase1recruitingnot on this map

Fecal Microbiota Transplantation (Autologous) in Infants Treated With Antibiotics

TypeinterventionalSponsorRutgers, The State University of New JerseyRan2024 to 2028Enrolled100ConditionsAntibiotic TreatmentArmsautologous fecal matter transplant
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Haipeng SunDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey, USA.
Anna DulencinDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey, USA.
Thomas J KirnDepartment of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Jasmine VoDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University New Brunswick, Piscataway, New Jersey, USA.
Ivan LiachkoPhase Genomics, Seattle, Washington, USA.
Deeptha RaoDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey, USA.
Joseph Manzano-SantanaDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey, USA.
Ekta PatelDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey, USA.
Connie LooiDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey, USA.
Daniel B HortonDepartment of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Emily BarrettDepartment of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA.
Melissa WeidnerDepartment of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Gloria BachmannDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Reynold A PanettieriRutgers Institute for Translational Medicine and Science, New Brunswick, New Jersey, USA.
Bradley A ConnorThe New York Center for Travel and Tropical Medicine, Weill Cornell Medical College, New York, New York, USA.
Marina RogovaThe New York Center for Travel and Tropical Medicine, Weill Cornell Medical College, New York, New York, USA.
Dorottya Nagy-SzakalBiotia Laboratory, Queens, New York, USA.ORCID 0009-0003-5972-6973
Mara Couto-RodriguezBiotia Laboratory, Queens, New York, USA.
Shashikant KotwalDepartment of Plant Biology, Rutgers University New Brunswick, New Brunswick, New Jersey, USA.
Qingli WuDepartment of Plant Biology, Rutgers University New Brunswick, New Brunswick, New Jersey, USA.
James SimonDepartment of Plant Biology, Rutgers University New Brunswick, New Brunswick, New Jersey, USA.
Martin J BlaserCenter for Advanced Biotechnology and Medicine, Rutgers University New Brunswick, Piscataway, New Jersey, USA.ORCID 0000-0003-2447-2443
Maria Gloria Dominguez BelloDepartment of Biochemistry and Microbiology, Rutgers University, New Brunswick, New Jersey, USA.ORCID 0000-0002-8879-6159

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic exposure during infancy disrupts gut microbiome assembly during a critical developmental window. Strategies to restore these ecosystems remain limited. In the REPAIR trial (NCT06609980), eight infants were followed longitudinally; two received amoxicillin for otitis media, and one subsequently underwent autologous fecal microbiota transplantation (aFMT) using stool collected prior to antibiotic exposure. Shotgun metagenomics, Hi-C-assisted resistome profiling, and untargeted metabolomics were performed on samples collected before and after antibiotics. Amoxicillin treatment was associated with displacement of community structure, enrichment of antibiotic resistance genes (ARGs), and altered fecal metabolites, including short-chain fatty acids, bile acids, acylcarnitines, bilirubin derivatives, tricarboxylic acid (TCA) cycle metabolites, and amino acids. In the non-restored infant, microbiota composition and ARG profiles remained persistently altered during follow-up, accompanied by sustained metabolic divergence. In contrast, the aFMT-treated infant demonstrated convergence toward pre-antibiotic community structure, directional restructuring of ARG carriers -including reduction of β-lactam and tetracycline resistance genes- and metabolite profiles trending toward the pre-antibiotic baseline across analytical platforms. Although limited to a case-based comparison, these findings provide integrated ecological and functional evidence that aFMT may promote recovery following antibiotic perturbation during early-life microbiome development and support the rationale for larger controlled clinical trials. IMPORTANCE: Antibiotic exposure in early life disrupts the developing gut microbiome during a critical window of host-microbe interaction. However, the extent to which these disturbances resolve naturally, or can be actively reversed, remains unclear. In this study, we use longitudinal sampling in infants to examine microbiome recovery following antibiotics, with and without autologous fecal microbiota transplantation (aFMT). We show that antibiotic exposure leads to coordinated disruptions in microbial composition, antibiotic resistance genes, and metabolic profiles. While partial recovery spontaneously occurs over time, faster and more extensive restoration toward the pre-antibiotic state is observed following aFMT. These findings provide insight into the ecological dynamics of microbiome reassembly in early life and highlight the potential of using controlled perturbations to understand microbiome resilience. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT06609980.

Indexed as

Anti-Bacterial AgentsFecal Microbiota TransplantationGastrointestinal MicrobiomeMetabolomeAmoxicillinFecesFemaleHumansInfantLongitudinal StudiesMaleMetagenomicsAmoxicillinAnti-Bacterial Agentsantibiotic perturbationfecal microbiota transplantationinfant microbiome

Identifiers

PMID42214386
PMCPMC13343926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.